Ingelheim, Germany, 10 June 2016, The Shareholders have decided to appoint Simone Menne to the Board of Managing Directors of Boehringer Ingelheim with effect from 1 September 2016. On this date she will assume responsibility for the Corporate Board Division Finance. She succeeds Hubertus von Baumbach who, as previously announced, will become Chairman of the Board of Managing Directors on 1 July 2016. He will also continue to be responsible for the Corporate Board Division Finance until 31 August 2016.
Christian Boehringer, Chairman of the Shareholders‘ Committee, states: “Ms. Simone Menne is a distinguished figure in the field of finance with many years of successful experience in Germany and abroad. Previously, she held strategic and operational responsibility in various roles. She is therefore thoroughly familiar with the key tasks and challenges faced by a multinational corporation based in Germany.”
Prof Andreas Barner, Chairman of the Board of Managing Directors, says: “We are delighted that Simone Menne has accepted our invitation to join the Board of Managing Directors of Boehringer Ingelheim and, together with her colleagues, actively shape the future of our company. We have come to know Ms. Menne as someone who not only possesses considerable specialist expertise, but who is very open and respectful in her dealings with people. We believe that her experience will enrich the company."
About Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative “Making More Health” while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.
In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information please visit www.boehringer-ingelheim.com